These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24853718)

  • 1. Calcitonin gene-related peptide inhibits osteolytic factors induced by osteoblast in co-culture system with breast cancer.
    Zhao H; Ning LL; Wang ZY; Li HT; Qiao D; Yao Y; Qin HL
    Cell Biochem Biophys; 2014 Nov; 70(2):1097-104. PubMed ID: 24853718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of calcitonin gene-related peptide on markers of bone metabolism in MG-63 osteoblast-like cells co-cultured with THP-1 macrophage-like cells under virtually osteolytic conditions.
    Jablonski H; Rekasi H; Jäger M
    BMC Musculoskelet Disord; 2016 May; 17():199. PubMed ID: 27141814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.
    Wang QP; Yang L; Li XP; Xie H; Liao EY; Wang M; Luo XH
    Bone; 2012 Sep; 51(3):515-23. PubMed ID: 22634178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors.
    Singh PP; van der Kraan AG; Xu J; Gillespie MT; Quinn JM
    Biochem Biophys Res Commun; 2012 May; 422(1):48-53. PubMed ID: 22561018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
    Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
    J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CGRP may regulate bone metabolism through stimulating osteoblast differentiation and inhibiting osteoclast formation.
    He H; Chai J; Zhang S; Ding L; Yan P; Du W; Yang Z
    Mol Med Rep; 2016 May; 13(5):3977-84. PubMed ID: 27035229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases.
    Bu G; Lu W; Liu CC; Selander K; Yoneda T; Hall C; Keller ET; Li Y
    Int J Cancer; 2008 Sep; 123(5):1034-42. PubMed ID: 18546262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-calcitonin gene-related peptide can reverse the catabolic influence of UHMWPE particles on RANKL expression in primary human osteoblasts.
    Kauther MD; Xu J; Wedemeyer C
    Int J Biol Sci; 2010 Sep; 6(6):525-36. PubMed ID: 20877694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
    Zong JC; Wang X; Zhou X; Wang C; Chen L; Yin LJ; He BC; Deng ZL
    Oncol Rep; 2016 Feb; 35(2):739-48. PubMed ID: 26573960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.
    Kapoor P; Suva LJ; Welch DR; Donahue HJ
    J Cell Biochem; 2008 Jan; 103(1):30-41. PubMed ID: 17471510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Knockdown of SOST in MDA-MB-231 breast cancer cells increase MG-63 osteoblast-like cell function in co-culture system].
    Cheng J; Guo D; Chen X; Wang T; Huang J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Nov; 32(11):1481-1485. PubMed ID: 27774939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
    Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
    Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
    Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.